Andretto de Mattos, B.; Tomas-Grau, R.H.; Alves Fernandes, T.A.; González-Lizárraga, F.; Tourville, A.; Ciss, I.; Brunel, J.-M.; Chehin, R.; Lannuzel, A.; Ferrié, L.;
et al. Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative. Biomolecules 2025, 15, 941.
https://doi.org/10.3390/biom15070941
AMA Style
Andretto de Mattos B, Tomas-Grau RH, Alves Fernandes TA, González-Lizárraga F, Tourville A, Ciss I, Brunel J-M, Chehin R, Lannuzel A, Ferrié L,
et al. Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative. Biomolecules. 2025; 15(7):941.
https://doi.org/10.3390/biom15070941
Chicago/Turabian Style
Andretto de Mattos, Bianca, Rodrigo Hernán Tomas-Grau, ThaÃs Antonia Alves Fernandes, Florencia González-Lizárraga, Aurore Tourville, Ismaila Ciss, Jean-Michel Brunel, Rosana Chehin, Annie Lannuzel, Laurent Ferrié,
and et al. 2025. "Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative" Biomolecules 15, no. 7: 941.
https://doi.org/10.3390/biom15070941
APA Style
Andretto de Mattos, B., Tomas-Grau, R. H., Alves Fernandes, T. A., González-Lizárraga, F., Tourville, A., Ciss, I., Brunel, J.-M., Chehin, R., Lannuzel, A., Ferrié, L., Raisman-Vozari, R., Figadère, B., Del Bel, E., & Michel, P. P.
(2025). Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative. Biomolecules, 15(7), 941.
https://doi.org/10.3390/biom15070941
